Heyholder
‹ Activism Filings

JW PHARMACEUTICAL Q3 operating profit KRW 29.0 billion, down 9.6% from a year earlier

JW PHARMACEUTICAL· Periodic Report

AI summary · Not investment advice

In Q3, the company sold KRW 212.1 billion and earned KRW 29.0 billion from its main business, down 9.6% from a year earlier and 13.2% from the prior quarter.

Operating profit · 3 months

KRW 29.0 billion

Key facts

Revenue (3 months)
KRW 212.1 billion
Net income (3 months)
KRW 20.2 billion
Period
Q3 (cumulative 2026.01.01 ~ 2026.09.30)
Revenue (prior-year 3 months)
KRW 200.0 billion
Revenue (year to date)
KRW 634.0 billion
Operating profit (prior-year 3 months)
KRW 32.0 billion
Operating profit (year to date)
KRW 95.9 billion
Net income (prior-year 3 months)
KRW 30.6 billion
Net income (year to date)
KRW 75.6 billion

Commentary

AI commentary · Not investment advice

What happened

JW Chungwae Pharmaceutical filed its quarterly report with consolidated results for the third quarter of 2026. Sales for the latest 3 months were KRW 212.07 billion. That is 6.0% higher than the same 3 months a year earlier. It is 4.5% lower than the previous quarter.

In the company's terms

Operating profit (profit from the core business) for the 3 months was KRW 28.95 billion. That is 9.6% lower than a year earlier and 13.2% lower than the previous quarter. The year-earlier figure was KRW 32.03 billion.

What changes for shareholders

Net income (the final profit after taxes and other costs) for the 3 months was KRW 20.20 billion. That is 34.0% lower than a year earlier and 27.6% lower than the previous quarter. The year-earlier figure was KRW 30.59 billion.

For the year to date, from January 1 to September 30, sales were KRW 633.97 billion. Operating profit was KRW 95.87 billion. Net income was KRW 75.75 billion.

Comments

No comments yet

Comments from shareholders will appear here.